首页 › 基金 › Pivotal bioVenture Partners Investment Advisor LLC › AVTX
Pivotal bioVenture Partners Investment Advisor LLC 对 AVTX 的持仓历史
AVALO THERAPEUTICS INC · 医疗保健
Pivotal bioVenture Partners Investment Advisor LLC 在 Q3 2026 的 13F 申报中披露持有 AVTX(AVALO THERAPEUTICS INC)434,033 股,市值约 US$6.7M,约占其申报组合的 2.71%,在其申报持仓中市值排名第 9 位。 Pivotal bioVenture Partners Investment Advisor LLC 最近 3 个申报季度中有 3 个季度披露了 AVTX 持仓,最早可追溯至 Q1 2026。
最后更新: 2026-11-14 · 来源: SEC EDGAR Form 13F-HR
Pivotal bioVenture Partners Investment Advisor LLC 对 AVTX 的持仓演变
Pivotal bioVenture Partners Investment Advisor LLC 于 Q1 2026 首次披露 AVTX 持仓:295,933 股(约 US$4.4M)。 该持仓在 Q2 2026 达到峰值 434,033 股,市值约 US$8.0M。 在 3 次申报中,Pivotal bioVenture Partners Investment Advisor LLC 1 次增持、0 次减持、1 次保持不变。 最近一期申报(Q3 2026)显示持股 434,033 股、市值约 US$6.7M。 持仓曾出现大幅变动:Q2 2026 增持约 47% (随后一个季度股价下跌 17%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2026 | 295.93K | $4.42M | 新进 |
| Q2 2026 | 434.03K | $8.02M | 增持 |
| Q3 2026 | 434.03K | $6.65M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 AVTX 与 13F 数据
AVTX(AVALO THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 78 只申报持有 AVTX,申报仓位最大的包括:Deep Track Capital, LP (US$66.7M), Caligan Partners LP (US$58.5M), TCG Crossover Management, LLC (US$55.8M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 AVTX 的基金
- Deep Track Capital, LP 3.61M 股 · $66.71M · Q2 2026
- Caligan Partners LP 3.16M 股 · $58.47M · Q2 2026
- TCG Crossover Management, LLC 3.02M 股 · $55.76M · Q2 2026
- Affinity Asset Advisors, LLC 3.24M 股 · $49.74M · Q3 2026
- 法拉龙资本管理 2.50M 股 · $46.16M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 2.50M 股 · $46.16M · Q2 2026
- Avoro Capital Advisors LLC 2.33M 股 · $43.12M · Q2 2026
- BVF INC/IL 2.08M 股 · $38.36M · Q2 2026
- Nantahala Capital Management, LLC 2.14M 股 · $32.84M · Q3 2026
- Soleus Capital Management, L.P. 1.65M 股 · $30.58M · Q2 2026
- BRAIDWELL LP 1.63M 股 · $30.11M · Q2 2026
- Logos Global Management LP 1.15M 股 · $21.25M · Q2 2026
更多关于 Pivotal bioVenture Partners Investment Advisor LLC
常见问题
How long has Pivotal bioVenture Partners Investment Advisor LLC held AVTX?
Pivotal bioVenture Partners Investment Advisor LLC has disclosed AVTX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Pivotal bioVenture Partners Investment Advisor LLC's current position in AVTX?
As of Q3 2026, Pivotal bioVenture Partners Investment Advisor LLC holds 434.03K shares of AVTX (AVALO THERAPEUTICS INC), valued at $6.65M, representing 2.71% of its reported portfolio and ranking #9.
Has Pivotal bioVenture Partners Investment Advisor LLC been buying or selling AVTX?
In the latest 13F filing (Q3 2026), Pivotal bioVenture Partners Investment Advisor LLC held unchanged its position in AVTX. The position peaked in Q2 2026 at 434.03K shares.
Which other funds hold AVTX?
Other major institutional holders of AVTX include Deep Track Capital, LP, Caligan Partners LP, TCG Crossover Management, LLC, among 78 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.